Replies to post #164584 on Biotech Values

[zipjet]

Capaxone while a good drug, and a very significant advance when it was approved, is light on efficacy today.

It does not stop progression and the disease continues albeit at a slowed pace.

It will be very interesting to see if new lesions develop now that my wife is on Tecfidera.

Six years on Tysabri without any gadolinium enhancing plaques was better than we could have hoped.

[DewDiligence]

US third-party payers will strongly embrace generic Copaxone (according to Craig Wheeler on MNTA’s webcast today) because there are currently no US generic drugs for multiple sclerosis.